How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
43
NVO Quote, Financials, Valuation and Earnings
Last price:
$59.44
Seasonality move
:
13.18%
Day range:
$58.59 - $59.91
52-week range:
$43.08 - $93.80
Dividend yield:
2.91%
P/E ratio:
17.31x
P/S ratio:
5.67x
P/B ratio:
13.03x
Volume:
12.1M
Avg. volume:
21.1M
1-year change:
-30.36%
Market cap:
$264.1B
Revenue:
$42.1B
EPS (TTM):
$3.43
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NVO
Novo Nordisk A/S
|
$11.6B | $0.84 | 2.84% | -13.8% | $59.51 |
|
ASND
Ascendis Pharma A/S
|
$384.5M | $0.99 | 204.11% | -54.05% | $278.54 |
|
DBVT
DBV Technologies SA
|
$936.6K | -$0.17 | -- | -86.12% | $39.69 |
|
EVAX
Evaxion AS
|
$1.3M | -$0.25 | -100% | -99.68% | $14.19 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.8B | $10.83 | 19.66% | 41.09% | $846.85 |
|
VKTX
Viking Therapeutics, Inc.
|
-- | -$0.98 | -- | -131.2% | $93.39 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NVO
Novo Nordisk A/S
|
$59.43 | $59.51 | $264.1B | 17.31x | $0.58 | 2.91% | 5.67x |
|
ASND
Ascendis Pharma A/S
|
$226.10 | $278.54 | $13.8B | -- | $0.00 | 0% | 18.91x |
|
DBVT
DBV Technologies SA
|
$21.61 | $39.69 | $591.3M | -- | $0.00 | 0% | -- |
|
EVAX
Evaxion AS
|
$3.18 | $14.19 | $20.1M | -- | $0.00 | 0% | 2.13x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$741.45 | $846.85 | $77.9B | 17.84x | $0.88 | 0.48% | 5.62x |
|
VKTX
Viking Therapeutics, Inc.
|
$29.04 | $93.39 | $3.3B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NVO
Novo Nordisk A/S
|
37.33% | 1.230 | 6.46% | 0.46x |
|
ASND
Ascendis Pharma A/S
|
127.22% | -0.633 | 7.87% | 0.68x |
|
DBVT
DBV Technologies SA
|
23.24% | -3.671 | 5.85% | 1.41x |
|
EVAX
Evaxion AS
|
-- | 4.752 | -- | 2.80x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
7.97% | -0.094 | 3.34% | 4.22x |
|
VKTX
Viking Therapeutics, Inc.
|
0.11% | 0.864 | 0.03% | 27.41x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NVO
Novo Nordisk A/S
|
$8.9B | $3.7B | 41.85% | 68.76% | 31.74% | $4.8B |
|
ASND
Ascendis Pharma A/S
|
$219.4M | $12.9M | -34.4% | -880.05% | 5.15% | $1.3M |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$36.9M | -211.46% | -280.59% | -- | -$32.5M |
|
EVAX
Evaxion AS
|
-- | -$4.4M | -238.97% | -- | -54.59% | -- |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.3B | $898.6M | 13.68% | 14.93% | 23.13% | $1.4B |
|
VKTX
Viking Therapeutics, Inc.
|
-$114K | -$98.6M | -28.59% | -28.62% | -- | -$94M |
Novo Nordisk A/S vs. Competitors
-
Which has Higher Returns NVO or ASND?
Ascendis Pharma A/S has a net margin of 26.68% compared to Novo Nordisk A/S's net margin of -28.55%. Novo Nordisk A/S's return on equity of 68.76% beat Ascendis Pharma A/S's return on equity of -880.05%.
Company Gross Margin Earnings Per Share Invested Capital NVONovo Nordisk A/S76.12% $0.70 $42.7B ASNDAscendis Pharma A/S87.87% -$1.17 $751.5M -
What do Analysts Say About NVO or ASND?
Novo Nordisk A/S has a consensus price target of $59.51, signalling upside risk potential of 0.13%. On the other hand Ascendis Pharma A/S has an analysts' consensus of $278.54 which suggests that it could grow by 23.7%. Given that Ascendis Pharma A/S has higher upside potential than Novo Nordisk A/S, analysts believe Ascendis Pharma A/S is more attractive than Novo Nordisk A/S.
Company Buy Ratings Hold Ratings Sell Ratings NVONovo Nordisk A/S6 5 2 ASNDAscendis Pharma A/S13 0 0 -
Is NVO or ASND More Risky?
Novo Nordisk A/S has a beta of 0.665, which suggesting that the stock is 33.529% less volatile than S&P 500. In comparison Ascendis Pharma A/S has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.4%.
-
Which is a Better Dividend Stock NVO or ASND?
Novo Nordisk A/S has a quarterly dividend of $0.58 per share corresponding to a yield of 2.91%. Ascendis Pharma A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 35.93% of its earnings as a dividend. Ascendis Pharma A/S pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVO or ASND?
Novo Nordisk A/S quarterly revenues are $11.7B, which are larger than Ascendis Pharma A/S quarterly revenues of $249.6M. Novo Nordisk A/S's net income of $3.1B is higher than Ascendis Pharma A/S's net income of -$71.3M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 17.31x while Ascendis Pharma A/S's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 5.67x versus 18.91x for Ascendis Pharma A/S. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVONovo Nordisk A/S5.67x 17.31x $11.7B $3.1B ASNDAscendis Pharma A/S18.91x -- $249.6M -$71.3M
-
Which has Higher Returns NVO or DBVT?
DBV Technologies SA has a net margin of 26.68% compared to Novo Nordisk A/S's net margin of --. Novo Nordisk A/S's return on equity of 68.76% beat DBV Technologies SA's return on equity of -280.59%.
Company Gross Margin Earnings Per Share Invested Capital NVONovo Nordisk A/S76.12% $0.70 $42.7B DBVTDBV Technologies SA-- -$1.21 $68.9M -
What do Analysts Say About NVO or DBVT?
Novo Nordisk A/S has a consensus price target of $59.51, signalling upside risk potential of 0.13%. On the other hand DBV Technologies SA has an analysts' consensus of $39.69 which suggests that it could grow by 83.37%. Given that DBV Technologies SA has higher upside potential than Novo Nordisk A/S, analysts believe DBV Technologies SA is more attractive than Novo Nordisk A/S.
Company Buy Ratings Hold Ratings Sell Ratings NVONovo Nordisk A/S6 5 2 DBVTDBV Technologies SA4 0 1 -
Is NVO or DBVT More Risky?
Novo Nordisk A/S has a beta of 0.665, which suggesting that the stock is 33.529% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.166, suggesting its less volatile than the S&P 500 by 216.581%.
-
Which is a Better Dividend Stock NVO or DBVT?
Novo Nordisk A/S has a quarterly dividend of $0.58 per share corresponding to a yield of 2.91%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 35.93% of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVO or DBVT?
Novo Nordisk A/S quarterly revenues are $11.7B, which are larger than DBV Technologies SA quarterly revenues of --. Novo Nordisk A/S's net income of $3.1B is higher than DBV Technologies SA's net income of -$33M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 17.31x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 5.67x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVONovo Nordisk A/S5.67x 17.31x $11.7B $3.1B DBVTDBV Technologies SA-- -- -- -$33M
-
Which has Higher Returns NVO or EVAX?
Evaxion AS has a net margin of 26.68% compared to Novo Nordisk A/S's net margin of -64.14%. Novo Nordisk A/S's return on equity of 68.76% beat Evaxion AS's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NVONovo Nordisk A/S76.12% $0.70 $42.7B EVAXEvaxion AS-- -$1.01 $74K -
What do Analysts Say About NVO or EVAX?
Novo Nordisk A/S has a consensus price target of $59.51, signalling upside risk potential of 0.13%. On the other hand Evaxion AS has an analysts' consensus of $14.19 which suggests that it could grow by 346.15%. Given that Evaxion AS has higher upside potential than Novo Nordisk A/S, analysts believe Evaxion AS is more attractive than Novo Nordisk A/S.
Company Buy Ratings Hold Ratings Sell Ratings NVONovo Nordisk A/S6 5 2 EVAXEvaxion AS3 0 0 -
Is NVO or EVAX More Risky?
Novo Nordisk A/S has a beta of 0.665, which suggesting that the stock is 33.529% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NVO or EVAX?
Novo Nordisk A/S has a quarterly dividend of $0.58 per share corresponding to a yield of 2.91%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 35.93% of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVO or EVAX?
Novo Nordisk A/S quarterly revenues are $11.7B, which are larger than Evaxion AS quarterly revenues of $37.5K. Novo Nordisk A/S's net income of $3.1B is higher than Evaxion AS's net income of -$4.9M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 17.31x while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 5.67x versus 2.13x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVONovo Nordisk A/S5.67x 17.31x $11.7B $3.1B EVAXEvaxion AS2.13x -- $37.5K -$4.9M
-
Which has Higher Returns NVO or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of 26.68% compared to Novo Nordisk A/S's net margin of 21.74%. Novo Nordisk A/S's return on equity of 68.76% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.
Company Gross Margin Earnings Per Share Invested Capital NVONovo Nordisk A/S76.12% $0.70 $42.7B REGNRegeneron Pharmaceuticals, Inc.85.9% $7.86 $34B -
What do Analysts Say About NVO or REGN?
Novo Nordisk A/S has a consensus price target of $59.51, signalling upside risk potential of 0.13%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $846.85 which suggests that it could grow by 12.75%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Novo Nordisk A/S, analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Novo Nordisk A/S.
Company Buy Ratings Hold Ratings Sell Ratings NVONovo Nordisk A/S6 5 2 REGNRegeneron Pharmaceuticals, Inc.17 8 0 -
Is NVO or REGN More Risky?
Novo Nordisk A/S has a beta of 0.665, which suggesting that the stock is 33.529% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.
-
Which is a Better Dividend Stock NVO or REGN?
Novo Nordisk A/S has a quarterly dividend of $0.58 per share corresponding to a yield of 2.91%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.48% to investors and pays a quarterly dividend of $0.88 per share. Novo Nordisk A/S pays 35.93% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVO or REGN?
Novo Nordisk A/S quarterly revenues are $11.7B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Novo Nordisk A/S's net income of $3.1B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 17.31x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 5.67x versus 5.62x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVONovo Nordisk A/S5.67x 17.31x $11.7B $3.1B REGNRegeneron Pharmaceuticals, Inc.5.62x 17.84x $3.9B $844.6M
-
Which has Higher Returns NVO or VKTX?
Viking Therapeutics, Inc. has a net margin of 26.68% compared to Novo Nordisk A/S's net margin of --. Novo Nordisk A/S's return on equity of 68.76% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.
Company Gross Margin Earnings Per Share Invested Capital NVONovo Nordisk A/S76.12% $0.70 $42.7B VKTXViking Therapeutics, Inc.-- -$0.81 $713.8M -
What do Analysts Say About NVO or VKTX?
Novo Nordisk A/S has a consensus price target of $59.51, signalling upside risk potential of 0.13%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 221.59%. Given that Viking Therapeutics, Inc. has higher upside potential than Novo Nordisk A/S, analysts believe Viking Therapeutics, Inc. is more attractive than Novo Nordisk A/S.
Company Buy Ratings Hold Ratings Sell Ratings NVONovo Nordisk A/S6 5 2 VKTXViking Therapeutics, Inc.12 1 0 -
Is NVO or VKTX More Risky?
Novo Nordisk A/S has a beta of 0.665, which suggesting that the stock is 33.529% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.710, suggesting its less volatile than the S&P 500 by 28.988%.
-
Which is a Better Dividend Stock NVO or VKTX?
Novo Nordisk A/S has a quarterly dividend of $0.58 per share corresponding to a yield of 2.91%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 35.93% of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVO or VKTX?
Novo Nordisk A/S quarterly revenues are $11.7B, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Novo Nordisk A/S's net income of $3.1B is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 17.31x while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 5.67x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVONovo Nordisk A/S5.67x 17.31x $11.7B $3.1B VKTXViking Therapeutics, Inc.-- -- -- -$90.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
